99 related articles for article (PubMed ID: 23856074)
21. Vitamin D analog calcitriol for breast cancer therapy; an integrated drug discovery approach.
B S N; P K KN; Akey KS; Sankaran S; Raman RK; Natarajan J; Selvaraj J
J Biomol Struct Dyn; 2023 Dec; 41(20):11017-11043. PubMed ID: 37054526
[TBL] [Abstract][Full Text] [Related]
22. Rapamycin in preventive (very low) doses.
Kondratov RV; Kondratova AA
Aging (Albany NY); 2014 Mar; 6(3):158-9. PubMed ID: 24670390
[No Abstract] [Full Text] [Related]
23. Targeting cancer stem cells in solid tumors by vitamin D.
So JY; Suh N
J Steroid Biochem Mol Biol; 2015 Apr; 148():79-85. PubMed ID: 25460302
[TBL] [Abstract][Full Text] [Related]
24. Vitamin D and Breast Cancer: Mechanistic Update.
Welsh J
JBMR Plus; 2021 Dec; 5(12):e10582. PubMed ID: 34950835
[TBL] [Abstract][Full Text] [Related]
25. Promotion of epithelial hyperplasia by interleukin-8-CXCR axis in human prostate.
Smith DK; Hasanali SL; Wang J; Kallifatidis G; Morera DS; Jordan AR; Terris MK; Klaassen Z; Bollag R; Lokeshwar VB; Lokeshwar BL
Prostate; 2020 Sep; 80(12):938-949. PubMed ID: 32542667
[TBL] [Abstract][Full Text] [Related]
26. The role of natural products in revealing NRF2 function.
Zhang DD; Chapman E
Nat Prod Rep; 2020 Jun; 37(6):797-826. PubMed ID: 32400766
[TBL] [Abstract][Full Text] [Related]
27. Vitamin D and breast cancer: Past and present.
Welsh J
J Steroid Biochem Mol Biol; 2018 Mar; 177():15-20. PubMed ID: 28746837
[TBL] [Abstract][Full Text] [Related]
28. Influence of vitamin D signaling on hormone receptor status and HER2 expression in breast cancer.
Zhang X; Harbeck N; Jeschke U; Doisneau-Sixou S
J Cancer Res Clin Oncol; 2017 Jul; 143(7):1107-1122. PubMed ID: 28025696
[TBL] [Abstract][Full Text] [Related]
29. Vitamin D compounds inhibit cancer stem-like cells and induce differentiation in triple negative breast cancer.
Shan NL; Wahler J; Lee HJ; Bak MJ; Gupta SD; Maehr H; Suh N
J Steroid Biochem Mol Biol; 2017 Oct; 173():122-129. PubMed ID: 27923595
[TBL] [Abstract][Full Text] [Related]
30. Targeting HER2 Positive Breast Cancer with Chemopreventive Agents.
Wahler J; Suh N
Curr Pharmacol Rep; 2015 Oct; 1(5):324-335. PubMed ID: 26442201
[TBL] [Abstract][Full Text] [Related]
31. Cancer Cell Growth Is Differentially Affected by Constitutive Activation of NRF2 by KEAP1 Deletion and Pharmacological Activation of NRF2 by the Synthetic Triterpenoid, RTA 405.
Probst BL; McCauley L; Trevino I; Wigley WC; Ferguson DA
PLoS One; 2015; 10(8):e0135257. PubMed ID: 26301506
[TBL] [Abstract][Full Text] [Related]
32. Commentary: Vitamin D and Pancreatic Cancer: A Pooled Analysis from the Pancreatic Cancer Case-Control Consortium.
Chirumbolo S
Front Oncol; 2015; 5():160. PubMed ID: 26301200
[No Abstract] [Full Text] [Related]
33. HES1-mediated inhibition of Notch1 signaling by a Gemini vitamin D analog leads to decreased CD44(+)/CD24(-/low) tumor-initiating subpopulation in basal-like breast cancer.
So JY; Wahler J; Das Gupta S; Salerno DM; Maehr H; Uskokovic M; Suh N
J Steroid Biochem Mol Biol; 2015 Apr; 148():111-21. PubMed ID: 25541438
[TBL] [Abstract][Full Text] [Related]
34. A synthetic triterpenoid CDDO-Im inhibits tumorsphere formation by regulating stem cell signaling pathways in triple-negative breast cancer.
So JY; Lin JJ; Wahler J; Liby KT; Sporn MB; Suh N
PLoS One; 2014; 9(9):e107616. PubMed ID: 25229616
[TBL] [Abstract][Full Text] [Related]
35. Inhibition of the transition of ductal carcinoma in situ to invasive ductal carcinoma by a Gemini vitamin D analog.
Wahler J; So JY; Kim YC; Liu F; Maehr H; Uskokovic M; Suh N
Cancer Prev Res (Phila); 2014 Jun; 7(6):617-26. PubMed ID: 24691501
[TBL] [Abstract][Full Text] [Related]
36. Oleanolic acid and its synthetic derivatives for the prevention and therapy of cancer: preclinical and clinical evidence.
Shanmugam MK; Dai X; Kumar AP; Tan BK; Sethi G; Bishayee A
Cancer Lett; 2014 May; 346(2):206-16. PubMed ID: 24486850
[TBL] [Abstract][Full Text] [Related]
37. Oral administration of a gemini vitamin D analog, a synthetic triterpenoid and the combination prevents mammary tumorigenesis driven by ErbB2 overexpression.
So JY; Wahler JE; Yoon T; Smolarek AK; Lin Y; Shih WJ; Maehr H; Uskokovic M; Liby KT; Sporn MB; Suh N
Cancer Prev Res (Phila); 2013 Sep; 6(9):959-70. PubMed ID: 23856074
[TBL] [Abstract][Full Text] [Related]
38. Gemini vitamin D analog suppresses ErbB2-positive mammary tumor growth via inhibition of ErbB2/AKT/ERK signaling.
Lee HJ; So JY; DeCastro A; Smolarek A; Paul S; Maehr H; Uskokovic M; Suh N
J Steroid Biochem Mol Biol; 2010 Jul; 121(1-2):408-12. PubMed ID: 20304052
[TBL] [Abstract][Full Text] [Related]
39. Prevention and treatment of experimental estrogen receptor-negative mammary carcinogenesis by the synthetic triterpenoid CDDO-methyl Ester and the rexinoid LG100268.
Liby K; Risingsong R; Royce DB; Williams CR; Yore MM; Honda T; Gribble GW; Lamph WW; Vannini N; Sogno I; Albini A; Sporn MB
Clin Cancer Res; 2008 Jul; 14(14):4556-63. PubMed ID: 18628471
[TBL] [Abstract][Full Text] [Related]
40. Functional interaction between mouse erbB3 and wild-type rat c-neu in transgenic mouse mammary tumor cells.
Kim A; Liu B; Ordonez-Ercan D; Alvarez KM; Jones LD; McKimmey C; Edgerton SM; Yang X; Thor AD
Breast Cancer Res; 2005; 7(5):R708-18. PubMed ID: 16168116
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
